Irritable bowel syndrome: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• GLP-1 0

EU-13 is a filter, not a ranking: it only narrows the list.

No research groups match this view yet.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Sex Differences in Effectiveness of CBT on IBS Project 3

  NCT05155631· University of California, Los Angeles· Updated 5 Nov 2026

  “Early termination due to unexpected closure of Mahana app. This caused a premature end to study enrollment.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

  NCT04612803· University of Cincinnati· Updated 4 Sept 2026

  “no funding for clinical research space”Registry text, quoted unchanged. Source

• Withdrawn

  Mindfulness Training Versus Low (FODMAP) Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols Diet

  NCT05630703· Wake Forest University Health Sciences· Updated 23 Apr 2026

  “The study was withdrawn prior to initiation. No participants were enrolled.”Registry text, quoted unchanged. Source

• Withdrawn

  GUT LINK: A Study of a Care Pathway Across Primary and GI Specialty Care

  NCT05725954· Michael Stewart· Updated 13 Apr 2026

  “Intervention (GUT LINK Tool) was implemented outside of the context of a research study at our care centre, the QEII, as quality improvement. It became infeasible to consent all physicians to use the tool, and carry out this study.”Registry text, quoted unchanged. Source

• Suspended

  Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

  NCT04306939· University of Pittsburgh· Updated 7 Jan 2026

  “Suspended for analysis and to consider further enrollment.”Registry text, quoted unchanged. Source

• Terminated

  Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

  NCT06153420· CinPhloro Pharma, LLC· Updated 15 Dec 2025

  “The study was terminated due to lack of efficacy compared to placebo.”Registry text, quoted unchanged. Source

• Terminated

  Low-FODMAP Diet for Functional Abdominal Pain Disorders in Children.

  NCT04528914· Medical University of Warsaw· Updated 1 Aug 2025

  “Preliminary results found that there is no difference on abdominal pain intensity between low-FODMAP and regular diet at 4 weeks. Moreover, both diets were difficult to adhere by patients. We do not expect any significant change in our findings.”Registry text, quoted unchanged. Source

• Withdrawn

  Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

  NCT05453916· Sadat City University· Updated 14 Jul 2025

  “Institutional and funding constrains”Registry text, quoted unchanged. Source

• Terminated

  Feasibility of an Online Cognitive Behavioural Therapy Application (Mahana IBS™, Mahana Therapeutics) in the Management of Irritable Bowel Syndrome

  NCT07008404· Nottingham University Hospitals NHS Trust· Updated 22 Jun 2025

  “Producer decided to stop commercialization of the Mahana app”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

  NCT07545772· Eli Lilly and Company· Source

• A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

  NCT07545759· Eli Lilly and Company· Source

• Lactic Acid Bacteria in Functional Diarrheal Disorders

  NCT07916688· Szeged University· Source

• A Personalized Approach to Abdominal Pain in Irritable Bowel Syndrome

  NCT05998577· Maastricht University Medical Center· Source

• A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

  NCT07519395· GlaxoSmithKline· Source

• Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children

  NCT03339128· AbbVie· Source

• GI Alpha-Gal Study

  NCT06268717· University of North Carolina, Chapel Hill· Source

• Applications of a Functional Dairy Product in Diet Therapy

  NCT07793487· Warsaw University of Life Sciences· Source

• Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome

  NCT07699926· My Myracle Sdn.Bhd· Source

• Clinical Efficacy and Safety of Jingfang Granules in Treating Diarrhea-Predominant Irritable Bowel Syndrome With Cold-Dampness Disturbing Spleen Syndrome

  NCT07688161· Nanjing First Hospital, Nanjing Medical University· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

See which targets of this disease your abstract mentions, and go to the people working on them.